(Q33435327)

26 July 2017

title

Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor (English)

1 reference

26 July 2017

1 reference

Susan L Ford

1

1 reference

26 July 2017

Y Sunila Reddy

2

1 reference

26 July 2017

Maggie T Anderson

3

1 reference

26 July 2017

Sharon C Murray

4

1 reference

26 July 2017

Pedro Fernandez

5

1 reference

26 July 2017

Daniel S Stein

6

1 reference

26 July 2017

Mark A Johnson

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Antimicrobial Agents and Chemotherapy

26 July 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 July 2017

volume

50

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

2201-2206

1 reference

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

21 June 2018

HIV-protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

Low-dose ritonavir moderately enhances nelfinavir exposure

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1479152

Dose-finding study of a once-daily indinavir/ritonavir regimen

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16723584

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.01490-05

1 reference

26 July 2017

1 reference

26 July 2017

1 reference